Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (DNTH) granted equity inducement awards on September 1, 2026 to four newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the independent Compensation Committee as material inducements for employment.
The inducement grants consist of non-qualified stock options to purchase an aggregate of 52,000 shares of common stock, with a 10-year term and an exercise price of $106.62 per share. The options vest 25% on the first anniversary of the vesting commencement date and then in equal monthly installments over the following 36 months. The grants are subject to the company’s Equity Inducement Plan and individual stock option agreements.
Dianthus Therapeutics (Nasdaq: DNTH) announced participation in three September 2026 investor conferences. At the Wells Fargo 21st Annual Healthcare Conference on September 8, executives will hold one-on-one meetings. CEO Marino Garcia will join fireside chats at Citi's Biopharma Back to School Conference on September 9 and the Cantor Global Healthcare Conference on September 10, alongside additional one-on-one investor meetings. Webcasts of the Citi and Cantor presentations will be available through the Investors section of the Dianthus Therapeutics website.
Agomab Therapeutics (Nasdaq: AGMB) announced that its Board has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive directors, subject to shareholder approval at a Special General Meeting on September 11, 2026 in Antwerp, Belgium. Garcia is President, CEO and director of Dianthus Therapeutics (Nasdaq: DNTH), while Dr. Patel is Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP).
Agomab will also hold an Extraordinary General Shareholders’ Meeting the same day at 2:30 PM CEST to seek approval for a proposed consolidation and split of outstanding pre-IPO warrants, adjusting each warrant to reflect the share split implemented with Agomab’s February 2026 IPO. Meeting materials and detailed biographies are available on Agomab’s investor website.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q2 2026 results and highlighted progress across its neuromuscular and rheumatology franchises. The company is advancing claseprubart, an investigational aC1s inhibitor, in three late‑stage neuromuscular programs, including the Phase 3 EMERGE registrational trial in generalized myasthenia gravis, initiated in June 2026 and evaluating 300mg/2mL subcutaneous dosing every two or four weeks, with top-line data expected in 2H 2028.
According to Dianthus, an interim responder analysis from the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial in CIDP showed a 75% response rate, above a 50% target based on prior aC1s inhibition, with favorable tolerability. The Phase 2 MoMeNtum trial in MMN exceeded its 36‑patient enrollment target and is expected to deliver top‑line results from 46 patients in December 2026. The FDA has agreed to remove ANA-based screening and monitoring requirements and reclassified a hypothetical SLE risk to drug‑induced lupus; no SLE or DIL cases have been observed.
Dianthus is also building a rheumatology franchise with DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor in an ongoing two‑part Phase 1 study in China, with healthy volunteer data anticipated by year end 2026 and initial indications prioritized in Sjögren’s disease, SLE and dermatomyositis. DNTH312, a first‑in‑class bifunctional fusion protein combining claseprubart and TACI and incorporating YTE half‑life extension, showed in vitro potency comparable to claseprubart and aims to be Phase 1 ready by year end 2027.
As of June 30, 2026, Dianthus reported approximately $1.2 billion in cash, cash equivalents and investments, which it expects will fund operations into 2030. Q2 2026 R&D expenses were $48.7 million versus $26.3 million a year earlier, and G&A expenses were $13.6 million versus $8.9 million. Net loss was $50.2 million, or $0.90 per share, compared to a net loss of $31.6 million, or $0.88 per share, in Q2 2025. License revenue grew to $0.8 million from $0.2 million. Total assets rose to $1.21 billion, including $1.18 billion of stockholders’ equity and an accumulated deficit of $427.8 million.
Dianthus Therapeutics (Nasdaq: DNTH) announced DNTH312, an investigational, first-in-class, extended half-life bifunctional fusion protein combining claseprubart and TACI for severe autoimmune diseases. DNTH312 is designed to inhibit active C1s (Classical Complement Pathway) and BAFF/APRIL (B‑cell modulation), two validated, complementary disease pathways.
According to Dianthus, DNTH312 showed in vitro aC1s inhibition and potency comparable to claseprubart, a non-human primate (NHP) half-life of 22 days similar to claseprubart, and similar single-dose IgM, IgA, and IgG reductions to BAFF/APRIL inhibitor povetacicept in NHPs. DNTH312 has expected IP protection through at least 2047 and is targeted to be Phase 1 ready by year-end 2027.
Dianthus Therapeutics (Nasdaq: DNTH) announced that on August 3, 2026, its independent Compensation Committee granted equity inducement awards to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). The grants consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock at an exercise price of $106.02 per share, with a 10-year term.
According to Dianthus, the options vest 25% on the first anniversary of the vesting commencement date and then in equal monthly installments over the following 36 months. The awards are issued under the company’s Equity Inducement Plan and individual stock option agreements.
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards on July 1, 2026 to five newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options for an aggregate 58,000 shares at an exercise price of $90.21 per share, with a 10-year term and four-year vesting schedule.
Dianthus Therapeutics (Nasdaq: DNTH) started the global Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (gMG) in AChR+ patients.
The placebo-controlled study will enroll ~195 participants, test Q2W and Q4W S.C. dosing, and target top-line results in 2H 2028.
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to three newly hired non-executive employees on June 1, 2026.
The awards are non-qualified stock options for an aggregate 60,000 shares at an exercise price of $89.45, with a 10-year term and a four-year vesting schedule.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in two investor conferences in June 2026. Executives will join fireside chats and host one-on-one investor meetings at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Live webcasts will be available via the company’s investor relations website under “News and Events”.